NCT05007106 2025-08-14
KEYVIBE-005
Merck Sharp & Dohme LLC
Phase 2 Completed
Clinical Trials
13 trialsNCT01032850 2021-06-02
Sorafenib With Capecitabine for Patients With Measurable Hepatocellular Carcinoma
New Mexico Cancer Research Alliance
Phase 2 Terminated
NCT02716766 2020-04-10
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
The University of Hong Kong
Phase 2 Completed
NCT03578874 2020-04-09
SECOX as Neoadjuvant Therapy in Patients With Locally Advanced HCC
The University of Hong Kong
Phase 2 Completed
NCT02042443 2017-09-12
S1310
National Cancer Institute (NCI)
Phase 2 Completed
NCT02089633 2017-07-28
PACOX
Bio-Cancer Treatment International Limited
Phase 2 Completed
NCT00483405 2017-07-12
NRR
UNC Lineberger Comprehensive Cancer Center
Phase 2 Completed
NCT03114085 2017-05-15
Apatinib Combined With Capecitabine Compared With Apatinib Treat Advanced Hepatocellular Carcinoma
First Affiliated Hospital of Guangxi Medical University
Phase 2 Unknown
NCT02576964 2016-11-02
A Study of Capecitabine (Xeloda) and Peginterferon Alfa-2a (Pegasys) in Treatment-Naive Participants With Advanced Liver Cancer
Hoffmann-La Roche
Phase 2 Completed
NCT00752063 2008-09-15
SECOX
The University of Hong Kong
Phase 2 Unknown
NCT00351195 2008-08-26
Etoposide, Oxaliplatin and Capecitabine in Advanced Hepatocellular Carcinoma (HCC)
Rigshospitalet, Denmark
Phase 2 Terminated
NCT00635323 2008-04-07
Safety And Efficacy Of Irinotecan Plus Capecitabine As First-Line Treatment In Asian Subjects With Hepatocellular Carcinoma
Pfizer
Phase 2 Completed
NCT00464295 2007-12-14
HCC-CAP
Aga Khan University
Phase 2 Completed